Ethical and legal implications of pharmacogenomics
- 1 March 2001
- journal article
- review article
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 2 (3) , 228-231
- https://doi.org/10.1038/35056075
Abstract
Pharmacogenomics is the application of genomics technology to the discovery and development of drugs. A greater understanding of the way in which individuals with a particular genotype respond to a drug allows manufacturers to identify population subgroups that will benefit most from a particular drug. The increasing emphasis on pharmacogenomics is likely to raise ethical and legal questions regarding, among other things, the design of research studies, the construction of clinical trials and the pricing of drugs.Keywords
This publication has 16 references indexed in Scilit:
- The Pharmaceutical Industry — To Whom is It Accountable?New England Journal of Medicine, 2000
- Pharmacogenetics and adverse drug reactionsThe Lancet, 2000
- Increasing demand while decreasing costs of generic medicinesThe Lancet, 2000
- The Pharmaceutical Industry — To Whom is It Accountable?New England Journal of Medicine, 2000
- What Makes Clinical Research Ethical?JAMA, 2000
- Pharmacogenetics and future drug development and deliveryThe Lancet, 2000
- Commentary: What “Community Review” Can and Cannot DoJournal of Law, Medicine & Ethics, 2000
- Involving Study Populations in the Review of Genetic ResearchJournal of Law, Medicine & Ethics, 2000
- Making Medicines Safer — The Need for an Independent Drug Safety BoardNew England Journal of Medicine, 1998
- Incidence of Adverse Drug Reactions in Hospitalized PatientsJAMA, 1998